Vertex Partners with GSK and Janssen on Phase II Studies of All-Oral HCV Treatment Regimens
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 11 (Table of Contents)
Published: 21 Nov-2012
DOI: 10.3833/pdr.v2012.i11.1837 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In a bid to advance the development of an all-oral, interferon-free treatment regimen for hepatitis C virus (HCV) infection, Vertex Pharmaceuticals has formed non-exclusive agreements with GlaxoSmithKline (GSK) and Janssen Pharmaceuticals to conduct separate Phase II proof-of-concept studies of its nucleotide analogue HCV polymerase inhibitor VX-135 in combination with GSK’s NS5A inhibitor GSK2336805 and with Janssen’s protease inhibitor simeprevir (TMC435), which is being developed with Medivir...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS